Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05867030
Status:
WITHDRAWN
Last Update Posted:
2023-10-17
First Post:
2023-04-10
Brief Title:
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Sponsor:
Innovent Biologics Suzhou Co Ltd
Organization:
Innovent Biologics Suzhou Co Ltd
Study Overview
Official Title:
A Phase IbIII Study to Evaluating the Efficacy and Safety of Parsaclisib in Combination With Rituximab and Lenalidomide Versus Rituximab in Combination With Lenalidomide in Subjects With Relapsed or Refractory Follicular Lymphoma
Status:
WITHDRAWN
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Development strategy adjustment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase IbIII Multicenter double-blinded study of Parsaclisib a PI3Kδ Inhibitor in Patients with Relapsed or Refractory Follicular Lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None